Digestive Disease Week 2016 (DDW2016, #DDW16) took place in San Diego last month. According to its website, it is the world’s largest gathering of doctors and researchers in the fields of gastroenterology, hepatology, endoscopy, and geastrointestinal surgery. This blog post is a collection of just some of the hep C topics discussed at the Digestive Disease Week 2016 that weren’t specifically about clinical trials for hep C treatment.
Hepatitis C Topics Presented at the Digestive Disease Week 2016
Access to Therapy in Era of All DAA Regimens: Real-World Experience From the TRIO Network by Douglas Dieterich, et al.
Summary: (American) The study looked at patients who had been denied treatment access and found that more than 33% of them had stage 3 or 4 liver fibrosis and were at risk of liver related health issues. The study’s abstract didn’t list the reasons why treatment had been denied.
- Caffeine is Associated with Decreased Risk of Advanced Hepatic Fibrosis in Patients with Chronic Hepatitis C: A Systematic Review and Meta-Analysis by Sikarin Upala, et al.
Summary: This review found that caffeine intake is significantly connected with a decreased risk of advanced fibrosis in hep C patients. This “…might be due to the antioxidant properties of caffeine and this substance also can reduce expression of expression of CYP1A2, which is correlated with fibrosis progression.” (Sikarin Upala, et al.) In conclusion, the review advised further study into this subject.
- Chronic Hepatitis C and Increased Risk of Gastrointestinal Malignancies by Sulieman Abdal Raheem, et al.
- HIV Coinfected Patients Have a Slow Regression of Fibrosis After Achieving SVR12 by Melinda S. Brown, et al.
Summary: The study found that in those co-infected with HIV/HCV liver fibrosis reversed at a slower rate after ‘curing’ hep C than it does in those who were only infected with hep C.
- Renal Function Decline Is Frequent in Patients Undergoing Hepatitis C Treatment Post Kidney Transplant by Kalyan R. Bhamidimarri, et al.
Conclusions: “HCV treatment with DAAs is feasible and effective post KT even in those who received HCV + graft. Renal function decline was frequent requiring tacrolimus dose adjustments in two thirds of the patients and there was 20% biopsy proven antibody mediated rejection. Close monitoring of renal graft function is necessary post KT while patients undergo HCV treatment.” (Kalyan R. Bhamidimarri, et al.)
The Additional Impact of Hepatitis C Infection on Cardiovascular Outcomes and Death Among Patients With Chronic Kidney Disease by Sara Tartof, et al.
Summary: Hep C adds to health issues and some cardiovascular outcomes in those with chronic kidney disease. Future assessments into whether new hep C treatments change this should be done.
- The Hepatitis C and HIV Co-Infected Patient: Time to Scale Up HCV Therapy at a Local Level by Alireza Meighan, et al.
Summary: (American) The study found that patients co-infected with HIV/HCV are under treated even after newer hep C treatments, able to treat patients co-infected demonstrated higher success rates, have been developed.
- Trends in Health Care Utilization for Hepatitis C Virus Infection in the United States by Vaibhav Wadhwa, et al.
Summary: The number of inpatient discharges for hepatitis C grew between 1998 and 2012, but the mortality rate has decreased. This has increased hospital admissions due to hep C in the US.
Additional information about the abstracts listed above or other abstracts that were part of Digestive Disease Week 2016 can be found in the Digestive Disease Week 2016’s online planner (click the abstracts tab and then the hepatitis C abstract category).